Cargando…

AI-powered drug repurposing for developing COVID-19 treatments

Emerging infectious diseases are an ever-present threat to public health, and COVID-19 is the most recent example. There is an urgent need to develop a robust framework to combat the disease with safe and effective therapeutic options. Compared to de novo drug discovery, drug repurposing may offer a...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhichao, Chen, Xi, Carter, Wendy, Moruf, Alicia, Komatsu, Takashi E., Pahwa, Sonia, Chan-Tack, Kirk, Snyder, Kevin, Petrick, Nicholas, Cha, Kenny, Lal-Nag, Madhu, Hatim, Qais, Thakkar, Shraddha, Lin, Yu, Huang, Ruili, Wang, Dong, Patterson, Tucker A., Tong, Weida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865759/
http://dx.doi.org/10.1016/B978-0-12-824010-6.00005-8
_version_ 1784655696447406080
author Liu, Zhichao
Chen, Xi
Carter, Wendy
Moruf, Alicia
Komatsu, Takashi E.
Pahwa, Sonia
Chan-Tack, Kirk
Snyder, Kevin
Petrick, Nicholas
Cha, Kenny
Lal-Nag, Madhu
Hatim, Qais
Thakkar, Shraddha
Lin, Yu
Huang, Ruili
Wang, Dong
Patterson, Tucker A.
Tong, Weida
author_facet Liu, Zhichao
Chen, Xi
Carter, Wendy
Moruf, Alicia
Komatsu, Takashi E.
Pahwa, Sonia
Chan-Tack, Kirk
Snyder, Kevin
Petrick, Nicholas
Cha, Kenny
Lal-Nag, Madhu
Hatim, Qais
Thakkar, Shraddha
Lin, Yu
Huang, Ruili
Wang, Dong
Patterson, Tucker A.
Tong, Weida
author_sort Liu, Zhichao
collection PubMed
description Emerging infectious diseases are an ever-present threat to public health, and COVID-19 is the most recent example. There is an urgent need to develop a robust framework to combat the disease with safe and effective therapeutic options. Compared to de novo drug discovery, drug repurposing may offer a lower-cost and faster drug discovery paradigm to explore potential treatment options of existing drugs. This chapter elucidates the advantages of artificial intelligence (AI) in enhancing the drug repurposing process from a data science perspective, using COVID-19 as an example. First, we elaborate on how AI-powered drug repurposing benefits from the accumulated data and knowledge of COVID-19 natural history and pathogenesis. Second, we summarize the pros and cons of AI-powered drug repurposing strategies to facilitate fit-for-purpose selection. Finally, we outline challenges of AI-powered drug repurposing from a regulatory perspective and suggest some potential solutions.
format Online
Article
Text
id pubmed-8865759
institution National Center for Biotechnology Information
language English
publishDate 2022
record_format MEDLINE/PubMed
spelling pubmed-88657592022-02-24 AI-powered drug repurposing for developing COVID-19 treatments Liu, Zhichao Chen, Xi Carter, Wendy Moruf, Alicia Komatsu, Takashi E. Pahwa, Sonia Chan-Tack, Kirk Snyder, Kevin Petrick, Nicholas Cha, Kenny Lal-Nag, Madhu Hatim, Qais Thakkar, Shraddha Lin, Yu Huang, Ruili Wang, Dong Patterson, Tucker A. Tong, Weida Reference Module in Biomedical Sciences Article Emerging infectious diseases are an ever-present threat to public health, and COVID-19 is the most recent example. There is an urgent need to develop a robust framework to combat the disease with safe and effective therapeutic options. Compared to de novo drug discovery, drug repurposing may offer a lower-cost and faster drug discovery paradigm to explore potential treatment options of existing drugs. This chapter elucidates the advantages of artificial intelligence (AI) in enhancing the drug repurposing process from a data science perspective, using COVID-19 as an example. First, we elaborate on how AI-powered drug repurposing benefits from the accumulated data and knowledge of COVID-19 natural history and pathogenesis. Second, we summarize the pros and cons of AI-powered drug repurposing strategies to facilitate fit-for-purpose selection. Finally, we outline challenges of AI-powered drug repurposing from a regulatory perspective and suggest some potential solutions. 2022 2022-02-23 /pmc/articles/PMC8865759/ http://dx.doi.org/10.1016/B978-0-12-824010-6.00005-8 Text en Copyright © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Liu, Zhichao
Chen, Xi
Carter, Wendy
Moruf, Alicia
Komatsu, Takashi E.
Pahwa, Sonia
Chan-Tack, Kirk
Snyder, Kevin
Petrick, Nicholas
Cha, Kenny
Lal-Nag, Madhu
Hatim, Qais
Thakkar, Shraddha
Lin, Yu
Huang, Ruili
Wang, Dong
Patterson, Tucker A.
Tong, Weida
AI-powered drug repurposing for developing COVID-19 treatments
title AI-powered drug repurposing for developing COVID-19 treatments
title_full AI-powered drug repurposing for developing COVID-19 treatments
title_fullStr AI-powered drug repurposing for developing COVID-19 treatments
title_full_unstemmed AI-powered drug repurposing for developing COVID-19 treatments
title_short AI-powered drug repurposing for developing COVID-19 treatments
title_sort ai-powered drug repurposing for developing covid-19 treatments
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865759/
http://dx.doi.org/10.1016/B978-0-12-824010-6.00005-8
work_keys_str_mv AT liuzhichao aipowereddrugrepurposingfordevelopingcovid19treatments
AT chenxi aipowereddrugrepurposingfordevelopingcovid19treatments
AT carterwendy aipowereddrugrepurposingfordevelopingcovid19treatments
AT morufalicia aipowereddrugrepurposingfordevelopingcovid19treatments
AT komatsutakashie aipowereddrugrepurposingfordevelopingcovid19treatments
AT pahwasonia aipowereddrugrepurposingfordevelopingcovid19treatments
AT chantackkirk aipowereddrugrepurposingfordevelopingcovid19treatments
AT snyderkevin aipowereddrugrepurposingfordevelopingcovid19treatments
AT petricknicholas aipowereddrugrepurposingfordevelopingcovid19treatments
AT chakenny aipowereddrugrepurposingfordevelopingcovid19treatments
AT lalnagmadhu aipowereddrugrepurposingfordevelopingcovid19treatments
AT hatimqais aipowereddrugrepurposingfordevelopingcovid19treatments
AT thakkarshraddha aipowereddrugrepurposingfordevelopingcovid19treatments
AT linyu aipowereddrugrepurposingfordevelopingcovid19treatments
AT huangruili aipowereddrugrepurposingfordevelopingcovid19treatments
AT wangdong aipowereddrugrepurposingfordevelopingcovid19treatments
AT pattersontuckera aipowereddrugrepurposingfordevelopingcovid19treatments
AT tongweida aipowereddrugrepurposingfordevelopingcovid19treatments